Flunitrazolam Blotters – 0.25mg

€ 1,00

Flunitrazolam Blotters are described as a laboratory research material associated with flunitrazolam, a synthetic triazolobenzodiazepine derivative. The supplied product information identifies a perforated paper presentation intended exclusively for controlled chemical identification, forensic analytical characterization, and laboratory documentation.

The stated chemical identifiers, purity, blotter content uniformity, independent testing, and transport compliance require supporting evidence before they can be considered verified. The labeled composition does not independently establish the actual amount or distribution of the compound within individual blotters.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-S-12518 Category:
Description

Flunitrazolam Blotters 0.25mg – Research Material

Product Overview

Flunitrazolam Blotters are described in the supplied information as a laboratory research material associated with flunitrazolam, a synthetic compound belonging to the triazolobenzodiazepine family.

The source identifies a perforated paper presentation carrying a specified nominal amount of the compound.

This presentation introduces analytical considerations that differ from those associated with an unformulated chemical powder, including substrate composition, distribution of the analyte, and the relationship between labeled content and measured content.

Raw Lab Chems presents the material exclusively within a Research Use Only framework.

The supplied information positions the product within forensic chemical identification, analytical characterization, and laboratory reference comparisons.

However, the product description alone does not establish the identity, purity, content uniformity, or actual composition of the supplied blotters. Flunitrazolam Blotters

The source also makes claims concerning independent laboratory testing, quality-system controls, and specialized transportation arrangements.

These remain unverified supplier statements unless supported by relevant records.

No clinical, therapeutic, diagnostic, consumer, or personal-use application is represented by this description.

Chemical Identity & Classification

Flunitrazolam Blotters is identified as a synthetic triazolobenzodiazepine derivative structurally related to Flunitrazolam Blotters.

The source describes a fused triazole-benzodiazepine ring system with fluorinated aromatic substituents and a nitro group.

The supplied chemical-reference information is:

  • Compound name: Flunitrazolam
  • Chemical class: Triazolobenzodiazepine derivative
  • Reported systematic designation: 3-(2-Fluorophenyl)-6-fluoro-1-methyl-8-nitro-4H-triazolo[4,3-a]benzodiazepine
  • Reported CAS Registry Number: 2243815-18-9
  • Reported molecular formula: C17H12F2N4O2
  • Reported molecular weight: 354.30 g/mol

These identifiers are reproduced from the supplied source and have not been independently confirmed against an authoritative chemical record.

The reported molecular formula and molecular weight require reconciliation. The formula C17H12F2N4O2 corresponds to an approximate molecular mass of 342.30 g/mol, rather than the stated 354.30 g/mol.      Flunitrazolam Blotters

The complete structural assignment should therefore be checked before the formula or molecular weight is published as a verified specification.

The source does not establish the actual batch identity through analytical records.

Researchers seeking public chemical-reference information may consult PubChem and confirm that any database entry corresponds to the precise compound under investigation.

Chemical & Physical Characteristics

The supplied product is described as perforated paper blotters.

No product photographs, substrate specifications, material-composition reports, or physical inspection records accompanied the source.

Accordingly, the actual paper characteristics, dimensions, coating, and other formulation components remain unverified.  Flunitrazolam Blotters

The chemical characteristics of flunitrazolam should be distinguished from the physical characteristics of the blotter substrate.

A reported molecular formula does not establish the solubility, thermal stability, environmental stability, or analytical recovery of the complete preparation.

The source references physicochemical behavior, chromatographic separation, and spectroscopic signatures as research topics.

No verified melting point, quantitative solubility profile, thermal-decomposition data, or experimentally established substrate compatibility information was provided.

The source recommends storage under freezer conditions with protection from light, air, and moisture.

However, no validated stability report, packaging qualification, or shelf-life determination accompanied that recommendation.

Storage claims should therefore be treated as provisional until substantiated by product-specific evidence.

Purity & Analytical Verification

The supplied information claims typical compound purity of at least 98%, reportedly established using HPLC.

No actual batch-specific chromatogram, Certificate of Analysis, mass spectrum, NMR report, or independent testing certificate was provided.

The purity claim therefore remains unverified.

The source references LC-MS/MS, LC-HRMS, UHPLC-QTOF, and other analytical platforms within the context of forensic chemical identification.

These techniques are relevant to analytical chemistry, but their inclusion in a product description does not establish that the supplied material has undergone validated testing.

An important distinction exists between the purity of a chemical ingredient and the measured content of a finished blotter.

Even if the purity of an ingredient were established, that result would not independently confirm the amount present in each paper unit or the consistency of its distribution.

The source claims analytical performance at trace concentrations but provides no validation dataset demonstrating specificity, accuracy, precision, or measurement uncertainty.

Likewise, no independent evidence establishes that the material qualifies as a certified reference material.

Researchers should rely on documented, batch-specific findings rather than catalog descriptions when evaluating analytical suitability.

Quality Control & Batch Integrity

The supplied source claims comprehensive batch testing, including chemical identity confirmation and examination of blotter uniformity.

It also refers to third-party testing by an ISO/IEC 17025-accredited laboratory.

No accreditation certificate, laboratory identity, scope of accreditation, or batch-specific analytical report was provided.

The claimed content-uniformity result of less than 3% relative standard deviation is likewise unsupported by accompanying measurements.

No documentation was supplied establishing batch traceability, formulation consistency, residual-solvent results, or long-term stability.

Consequently, these statements should be presented as supplier claims rather than verified product specifications.

For institutional laboratory records, useful information includes the product designation, supplier, batch identifier, receipt date, applicable safety documentation, and available analytical findings.

The distinction between supplier-provided information and independently verified evidence should remain clear throughout the inventory record.

No certification, accreditation, or guaranteed analytical performance is implied by this description.

Safety, Handling & Laboratory Precautions

Flunitrazolam belongs to a class of benzodiazepine-related substances that warrants strict institutional safety controls.

The material should be handled only within an authorized laboratory setting under an appropriate chemical-risk assessment.

Research personnel should consult applicable safety documentation, institutional procedures, and relevant legal requirements.

Safety controls should address restricted access, protective equipment, prevention of unintended contact, contamination management, secure inventory, and chemical-waste disposal.

The blotter presentation does not establish pharmaceutical suitability or safety for human or veterinary exposure.

Because the actual content and uniformity have not been independently verified, the nominal label must not be treated as an analytical measurement.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes resealable packaging, moisture protection, desiccants, and specialized transportation arrangements.

No packaging-validation report, container specification, or shipment-condition record accompanied these claims.

The source recommends storage at −20°C under conditions intended to limit exposure to light, moisture, and air.

No product-specific stability study was provided to establish the necessity or effectiveness of this temperature.

The source also claims transportation arrangements meeting IATA and DOT requirements.

No dangerous-goods classification, carrier authorization, or other compliance documentation was supplied to support that claim.

Appropriate packaging and transportation requirements depend on the applicable legal classification and the verified characteristics of the actual material.

Laboratory inventory records should preserve the product name, batch identifier where available, receipt information, and any documented storage conditions.

No verified shelf life or temperature-controlled shipping guarantee is asserted.

Intended Research Use & Market Positioning

The supplied scientific context places flunitrazolam within forensic and analytical research concerning designer benzodiazepines and related triazolobenzodiazepine structures.

Relevant research themes include chemical identification, analytical documentation, comparison of structurally related compounds, and evaluation of available reference information.

These are descriptions of institutional analytical contexts, not evidence that the supplied blotters meet certified reference-material requirements.

Raw Lab Chems also lists Fluetizolam Pellets, a separate benzodiazepine-related catalog material.

The supplied Flunitrazolam Blotters product reference identifies the specific presentation discussed here.

An additional Flunitrazolam Blotters catalog listing was supplied as a related reference.

These links provide catalog context only. They do not establish equivalence between different preparations, verified chemical content, or suitability for a particular analytical procedure.

Ordering, Availability & Fulfillment

The source describes international fulfillment, shipment tracking, protective packaging, and transport arrangements for research institutions.

No current inventory confirmation, destination-specific authorization, carrier documentation, or verified shipment records were supplied.

Consequently, no particular availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.

The source characterizes the material as a controlled research chemical and refers to Schedule I transportation requirements.

However, a universal Schedule I classification cannot be assumed. Controlled-substance scheduling and related restrictions depend on the relevant jurisdiction and the specific legal provisions in force.

Institutional acquisition, possession, transportation, importation, and exportation must comply with all applicable requirements.

Research-only labeling does not create an exemption from controlled-substance legislation.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flunitrazolam is a triazolobenzodiazepine derivative that may be subject to controlled-substance restrictions, including jurisdiction-specific scheduling, analog provisions, and import or export controls.

The legal status of the compound must be determined under the laws applicable to the relevant institution and jurisdiction.

Authorized researchers remain responsible for obtaining any necessary permissions and maintaining appropriate laboratory controls.

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Flunitrazolam Blotters – 0.25mg”
Shipping & Delivery